Search

everythinglearnresearchcommunity

for

Search:↓

A patient with complete hair loss regrew all her hair using tofacitinib.

Alopecia areata has a complex genetic basis that was not fully understood as of 2001.

Platelet-Rich Plasma (PRP) could potentially help regrow hair in people with Alopecia Areata, but more research is needed to confirm its effectiveness.

Niosomes are a promising and effective way to deliver drugs through the skin.

HIV-1 may cause increased stem cell death in hair follicles, leading to hair loss.

Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.

Lupus treatment requires a combination of drugs and therapies, with research needed for new options.

A combination of oral cyclosporin and PUVA treatment worked well for a severe skin condition called generalized pustular psoriasis.

Various treatments, including FDA-approved drugs, natural products, and oral supplements, can help with hair loss, but a patient's medical history and potential allergies should be considered when choosing a treatment.

Liposomes improve the delivery and effectiveness of cosmetic ingredients but face challenges like cost and stability.

The cause of alopecia areata was unknown, and while various treatments existed, no best treatment was agreed upon.

Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.

SARS-CoV-2, the virus causing COVID-19, can affect all endocrine organs and systems, altering their function and potentially leading to disorders. Factors like diabetes and obesity increase infection risk and severity. Understanding these effects is key for effective treatment.

Umbilical cord cells safely improve healing in long-term nonhealing wounds better than a placebo.

Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.

Two compounds from Asiasarum heterotropoides roots show potential as lung cancer treatments without harming normal cells.

Alternative treatments show promise for hair growth beyond traditional methods.

The document concludes that recognizing specific histological features of different nonscarring alopecias is crucial for accurate diagnosis and understanding hair loss progression.

Nanocarriers could improve how drugs are delivered through the skin but require more research to overcome challenges and ensure safety.

Botulinum toxin's effectiveness for treating scalp alopecia is not well-supported due to insufficient data.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

Adipose tissue shows promise for hair regrowth, but more research is needed to confirm best practices and effectiveness.

The document concludes that diagnosing and treating hair loss is complex and requires understanding its psychological effects and underlying causes, while also calling for more research and new treatments.

Common types of non-scarring hair loss have various causes and treatments, but more effective solutions are needed.

Inflammation and Demodex mites might contribute to hair loss, and targeting them could help treat it.

Fetal-maternal stem cells in a mother's hair can help with tissue repair and regeneration long after childbirth.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

Increasing PBX1 reduces aging and cell death in hair follicle stem cells by boosting SIRT1 and lowering PARP1 activity.

New protein changes may be involved in the immune attack on hair follicles in alopecia areata.

A substance called Vascular Endothelial Growth Factor can protect certain hair follicle stem cells from damage caused by androgens, suggesting a new possible treatment for hair loss.